维普期刊资源整合服务平台（V6.5）

73篇 您的检索式：作者名="MITA MM"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR inhibitor, administered Ⅳ daily X 5 every other week in patients (pts) with refractory or advanced malignanciSs显示文摘	Mita MM Rowinsky EK Goldston ML	2004	Clin Oncol2004，30，3：	1
2	Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，：	1
3	Survivin:key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
4	Survivin : key reg- ulator of mitosis and apoptosis and novel target for cancer therapeutics 显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
5	Survivin : key regulator of mitosis and apoptosis and novel target for cancer therapeutics 显示文摘	Mita AC Mita MM Nawrocki ST	2008	CIin Cancer Res2008，14，16：	1
6	Heat shock proteins: A potentional anticancer target 显示文摘	Sankhala KK Mira MM Mita AC	2011	Curr Drug Targets2011，12，：	1
7	A phase Ⅱ,pharmacokinetic,and biologic study of semaxanib and thalidomide in patients with metastatic melanoma显示文摘	Mita MM Rowinsky EK Forero L	2007	Cancer Chemother Pharmacol2007，59，2：	1
8	Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics 显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
9	Survivin:key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
10	Survivin:key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin cancer Res2008，14，16：	1
11	Survivin:key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
12	Survivin: key reg- ulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawroeki ST etal	2008	Clin Cancer Res2008，14，16：	1
13	Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics 显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
14	Survivin:key regulator ofmitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
15	Survivin: key reg-ulator of mitosis and apoptosis and novel target for cancertherapeutics 显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clin Cancer Res2008，14，：	1
16	Survivin:key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mira MM Nawrocki ST	2008	Clin Cancer Res2008，14，16：	1
17	Phase Ⅰ trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573;MK-8669) administered intravenously daily for 5 days every 2weeks to patients with advanced malignancies显示文摘	Mita MM Mita AC Chu QS		0，，：	1
18	Survivin:key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST		0，，16：	1
19	Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics 显示文摘	Mita AC Mita MM Nawroeki ST	2008	Clin Cancer Res2008，14，16：	1
20	Survivin:key regulator of mitosis and apoptosis and novel target for cancer therapeutics显示文摘	Mita AC Mita MM Nawrocki ST	2008	Clinical Cancer Research2008，14，6：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示